COVID impact on Clinical Trials
Tatiana Foroud, PhD Dec 20, 2021
As you all are aware, the demand for hospital care and services has markedly increased in the past few weeks. We have more COVID patients in our hospitals than we had in our fall surge. IU Health is currently caring for 518 COVID-19 patients throughout the system. This is an all-time high number of COVID patients at IU Health.
- There are 496 patients in ICU-level care, and 339 of those are COVID-19 patients.
- IU Health has added beds in additional spaces for patients needing ICU-level care.
- The number of ICU bed numbers at a hospital can change over time as non-ICU beds can be turned into ICU beds with the right staff and equipment.
In the context of the COVID surge and the pressing demands of caring for patients IU School of Medicine is assisting our IU Health partners by carefully evaluating and modulating clinical research requirements.
To help continue clinical research while accommodating needs for beds, inpatient services, and Investigational Drug Service (IDS), the following plan has been outlined and is being implemented:
- Pause all NEW recruits into existing studies and all NEW studies that require IDS or inpatient beds, or major hospital services (for example, radiology, etc.) that are needed while the hospital is FULL.
- Continue all COVID trials and any trials with potentially life-saving therapies (for example, cancer therapeutic trials).
- The anticipated resumption of inpatient trials is January 10th, but subject to change (pending reduction in strain on hospital capacity).
- This plan does NOT impact basic laboratory research.
Please contact Sharon Moe, Deb Broach or Laurie Trevino with questions.
Tatiana Foroud, PhD
Executive Associate Dean for Research Affairs, Indiana University School of Medicine Executive Vice President of Academic Affairs for Clinical Research, IU Health
Tatiana Foroud, PhD
Tatiana Foroud, PhD, is executive associate dean for research affairs at Indiana University School of Medicine and chair of the Department of Medical and Molecular Genetics. She is also executive vice president of academic affairs for clinical research at IU Health.
Dr. Foroud is a statistical geneticist and leader in dementia research. She runs the NIH-designated repository for blood, DNA, tissue and other samples collected from patients throughout the country with Alzheimer’s disease.